Evidence map›Paper›PMID 28496748›Full record

ReviewJournal of atrial fibrillation

Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation.

Anjan K Chakrabarti, Shalin J Patel, Payal Kohli, Jacob A Udell, Priyamvada Singh, Lakshmi Gopalakrishnan, Varun Kumar, C Michael Gibson

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of atrial fibrillation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Anjan K ChakrabartiCardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center (AKC, SJP, LG, VK, CMG), Harvard Medical School, Boston, MA; TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women?s Hospital (PK, JAU), Harvard Medical School, Boston, MA; and the PERFUSE Angiographic Core Laboratories and Data Coordinating Center, Beth Israel Deaconess Medical Center (PS) in Boston, MA.
Shalin J PatelCardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center (AKC, SJP, LG, VK, CMG), Harvard Medical School, Boston, MA; TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women?s Hospital (PK, JAU), Harvard Medical School, Boston, MA; and the PERFUSE Angiographic Core Laboratories and Data Coordinating Center, Beth Israel Deaconess Medical Center (PS) in Boston, MA.
Payal KohliCardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center (AKC, SJP, LG, VK, CMG), Harvard Medical School, Boston, MA; TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women?s Hospital (PK, JAU), Harvard Medical School, Boston, MA; and the PERFUSE Angiographic Core Laboratories and Data Coordinating Center, Beth Israel Deaconess Medical Center (PS) in Boston, MA.
Jacob A UdellCardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center (AKC, SJP, LG, VK, CMG), Harvard Medical School, Boston, MA; TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women?s Hospital (PK, JAU), Harvard Medical School, Boston, MA; and the PERFUSE Angiographic Core Laboratories and Data Coordinating Center, Beth Israel Deaconess Medical Center (PS) in Boston, MA.
Priyamvada SinghCardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center (AKC, SJP, LG, VK, CMG), Harvard Medical School, Boston, MA; TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women?s Hospital (PK, JAU), Harvard Medical School, Boston, MA; and the PERFUSE Angiographic Core Laboratories and Data Coordinating Center, Beth Israel Deaconess Medical Center (PS) in Boston, MA.
Lakshmi GopalakrishnanCardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center (AKC, SJP, LG, VK, CMG), Harvard Medical School, Boston, MA; TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women?s Hospital (PK, JAU), Harvard Medical School, Boston, MA; and the PERFUSE Angiographic Core Laboratories and Data Coordinating Center, Beth Israel Deaconess Medical Center (PS) in Boston, MA.
Varun KumarCardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center (AKC, SJP, LG, VK, CMG), Harvard Medical School, Boston, MA; TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women?s Hospital (PK, JAU), Harvard Medical School, Boston, MA; and the PERFUSE Angiographic Core Laboratories and Data Coordinating Center, Beth Israel Deaconess Medical Center (PS) in Boston, MA.
C Michael GibsonCardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center (AKC, SJP, LG, VK, CMG), Harvard Medical School, Boston, MA; TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women?s Hospital (PK, JAU), Harvard Medical School, Boston, MA; and the PERFUSE Angiographic Core Laboratories and Data Coordinating Center, Beth Israel Deaconess Medical Center (PS) in Boston, MA.
Beth Israel Deaconess Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-valvular atrial fibrillation is the most common arrhythmia encountered in clinical practice and is associated with substantial healthcare costs. The risk of thromboembolic stroke is 3-5 times higher in patients with atrial fibrillation compared with the general population. Until the recent emergence of direct thrombin (factor IIa) and factor Xa inhibitors, antithrombotic therapy for atrial fibrillation was achieved with antiplatelet agents or vitamin K antagonists, which are considered cost-effective strategies when compared to no treatment. Now newer agents, such as the direct thrombin inhibitor dabigatran, can lower thromboembolic events and reduce the risk of fatal and intracerebral hemorrhage compared with warfarin, in addition to eliminating the need for costly therapeutic monitoring. Multiple analyses have shown that dabigatran, when compared with warfarin therapy that achieves a time in therapeutic range (TTR) consistent with previous large-scale trials, is a cost-effective approach to antithrombotic therapy in atrial fibrillation, ranging from $16,385 to $86,000 per quality-adjust life-year (QALY) gained. It has been shown to be especially cost-effective (QALY < $50,000) for high stroke-risk patients, those with a CHADS

Identifiers

PMID28496748
PMCPMC5153083
OpenAlexW2183547666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.